CSL trades at decade-low P/E despite growth. Explore Seqirus demerger plans, margin recovery risks, and upside potential—read ...

Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...

Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...

Shares of the Australia-based CSL Ltd. (AU:CSL) fell by over 4% as of writing despite the company achieving higher profit in FY24. The company reported an NPAT (net profit after tax) attributable to ...

As investors, we’re irresistibly drawn to milestones, and the past year has provided a jackpot of them. The ASX stormed past 8,000, Bitcoin soared beyond US$100,000, NVIDIA hit a mind-boggling US$3 ...

ADRs of CSL Limited (OTCQX:CSLLY) dropped ~16% on Tuesday as Wall Street reacted to Australian biotech’s plans to lay off 15% of its workforce, announced in conjunction with its fiscal 2025 financials ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...

Australian biotech giant CSL Ltd CSL.AX' reported on Tuesday a net profit rise of 13% in the first half, bolstered by strong demand and increased plasma collection at its Behring unit. The company, ...

CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...

This biotech giant could have major upside potential in 2026. The post A once-in-a-decade opportunity to buy CSL shares?